Niagen Bioscience Secures IV and Injectable Formulation Patent Extending IP to 2044
Niagen Bioscience received U.S. Patent No. 12,558,367 covering IV and injectable formulations and methods of use for nicotinamide riboside, extending exclusivity through 2044. The patent bolsters its Niagen Plus portfolio designed for faster NAD+ infusions without severe side effects and supports expansion across 1,200+ U.S. clinics.
1. Patent Details
Niagen Bioscience secured U.S. Patent No. 12,558,367 covering methods of use and formulations for intravenous and injectable nicotinamide riboside, with protection through 2044. Claims span aqueous-based formulations, multiple administration routes, defined dosage parameters, select NR salt forms, and combination use with other NAD+ precursors.
2. Enhanced Niagen Plus Formulation
Under its Niagen Plus portfolio, the company developed a pharmaceutical-grade intravenous NR delivery that enables faster infusions and higher NAD+ elevation without severe side effects, enhancing patient comfort and cellular NAD+ boosting efficiency.
3. Commercial Footprint Growth
Niagen IV is available at over 1,200 healthcare, wellness, and longevity clinics across the U.S., and the newly issued patent is expected to drive additional commercial pathways and partnerships, expanding the clinic network for injectable NAD+ therapies.
4. Strengthened IP Moat
This patent adds to Niagen Bioscience’s portfolio of over 100 patents, reinforcing its intellectual property moat in the fast-growing NAD+ boosting segment, deterring potential infringers and underlining the durability of its Niagen product portfolio.